Funded Grants

Alzheimer’s Disease (AD) is a severe dementia that is likely a result of years of buildup in the brain of molecules called amyloid-beta oligomers (AβOs).

More than 1 in 100 individuals are diagnosed with Autism Spectrum Disorder (ASD), with profound impacts on the quality of life of those who are affected and their families.

Dr. Belzil began her research career as a PhD student at the Université de Montréal under the guidance of world renowned geneticist and Director of the Montreal Neurological Institute and Hospital, Dr. Guy Rouleau.

For this project Dr. Sanjay Kalra and his team aims to improve on current techniques to use magnetic resonance imaging (MRI) as a readily available way to examine if a potential new treatment is working to slow down progression of ALS.

Tissue engineering is a process that was originally designed and continues to be used for growing cells outside the body, turning them into functional tissues and organs, and applying them for clinical use.

The team wants to take a new breakthrough technology called Cyto-iGluSnFR (pronounced “sight-oh-eye-glue-sniffer”) and adapt it for the discovery of drugs to treat a variety of brain and eye diseases.

Alzheimer’s disease (AD) is a severely disabling illness with biological causes that are not well understood. Abnormalities in gene function impacts brain activities and could cause AD.

Dr. Lutz is currently completing his post-doctoral fellowship entitled “Epigenetic mechanisms of childhood maltreatment”, in which he investigates the strong relationship between childhood malnutrition and mental health outcomes.

This project proposes to integrate the low-invasive, non-lethal in vivo sampling/sample preparation SPME approach with MS detection to obtain the full profile of brain metabolome and lipidome, the quantification of drugs and monitoring of their metabolism, selective extraction of target compounds (drugs or selected endogenous metabolite), as well as high resolution chemical imaging of deep brain structure.

The existence of different strains of misshapen proteins in the brains of Alzheimer’s disease (AD) patients is emerging as an obstacle to the development of effective treatments.